FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 222 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... November 8, 2024 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma August 12, 2021 Carriers of a Germline Pathogenic Variant in CDKN2A are at a... June 17, 2022 Load more HOT NEWS Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... Resource Round-Up: Let’s Win Pancreatic Cancer Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against...
